心血管領域的合作研究與授權協議（2016-2026 年）

本報告分析了心血管領域 650 多項合作研究和授權協議，清晰地、以證據為基礎地闡述了整個市場夥伴關係的設計、協商和執行方式。

目錄

摘要整理

第1章：引言

第2章：心血管合約的發展趨勢

• 介紹
• 過去幾年在心血管領域的合作
• 心血管合作項目：按合約類型分類
• 心血管合作：依產業分類
• 心血管合作：依發展階段
• 心血管合作：依技術類型分類
• 心血管協作：依治療指徵

第3章 心血管合作的財務協議條款

• 介紹
• 已披露的心血管合作項目的財務條款和條件
• 心血管合作項目的主要金額
• 心血管合約進展
• 心血管合約的里程碑付款
• 心血管領域權利金費率

第4章：心血管領域的主要合約和承包公司

• 介紹
• 在心血管領域合作方面最積極主動的公司
• 心血管領域最活躍的承包公司名單
• 心血管領域價值排名前列的合約

第5章：心血管領域的合約記錄

• 介紹
• 可提供合約的心血管合作協議

第6章：心血管收縮：依治療標靶分類

• 介紹
• 合約：透過心血管治療標靶
• 合約記錄
• 合約記錄 - 心血管合約：按公司分類 (AZ)
• 合約記錄 - 心血管合約：按技術類型分類
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

The definitive benchmark for cardiovascular dealmaking

Cardiovascular remains one of the most active and strategically important therapeutic areas for partnering, with deal structures varying widely across indications, modalities, and stages of development.

This report provides a comprehensive and structured analysis of 650+ cardiovascular collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cardiovascular deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within cardiovascular partnerships.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 650+ cardiovascular collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cardiovascular dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cardiovascular partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

• 2.1. Introduction
• 2.2. Cardiovascular partnering over the years
• 2.3. Cardiovascular partnering by deal type
• 2.4. Cardiovascular partnering by industry sector
• 2.5. Cardiovascular partnering by stage of development
• 2.6. Cardiovascular partnering by technology type
• 2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for cardiovascular partnering
• 3.3. Cardiovascular partnering headline values
• 3.4. Cardiovascular deal upfront payments
• 3.5. Cardiovascular deal milestone payments
• 3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in cardiovascular partnering
• 4.3. List of most active dealmakers in cardiovascular
• 4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

• 5.1. Introduction
• 5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by cardiovascular therapeutic target
• Deal directory
• Deal directory - Cardiovascular deals by company A-Z
• Deal directory - Cardiovascular deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cardiovascular partnering since 2016
• Figure 2: Cardiovascular partnering by deal type since 2016
• Figure 3: Cardiovascular partnering by industry sector since 2016
• Figure 4: Cardiovascular partnering by stage of development since 2016
• Figure 5: Cardiovascular partnering by technology type since 2016
• Figure 6: Cardiovascular partnering by indication since 2016
• Figure 7: Cardiovascular deals with a headline value
• Figure 8: Cardiovascular deals with upfront payment values
• Figure 9: Cardiovascular deals with milestone payment
• Figure 10: Cardiovascular deals with royalty rates
• Figure 11: Active cardiovascular dealmaking activity since 2016
• Figure 12: Top cardiovascular deals by value since 2016